Cas No.1169630-82-3, Semaglutide side chain, Semaglutide intermediate

Semaglutide offers a transformative approach to treating type 2 diabetes by improving glycemic control, reducing cardiovascular risks, and promoting weight loss. With its favorable safety profile and potential for improved patient outcomes, Semaglutide has tremendous value in the field of diabetes therapeutics. Seamlessly incorporate our intermediates into your manufacturing process, ensuring a steady supply of this exceptional medication. Join us in advancing diabetes management and improving patient health. Embrace Semaglutide and contribute to a healthier, more productive future.

This peptide chain, also known as the P29 main chain, is the backbond of Semaglutide. Two amine residues (labeled with A and B) need to be conjugated with 

- a Boc-protected dipeptide CAS No. 2061897-68-3, consisting of a 2-methyl-alanine and a histidine

- two units of ethylene glycol (H₂N-PEG2-CH₂-COOH), a glutamic acid, and a C18 fatty acid Octadecadioic acid, which form another side chain CAS No. 1169630-40-3. 

The structure of the peptide backbone (CAS RN. 1169630-82-3) with two amine residues highlighted.

A side chain CAS RN 2061897-68-3 to be conjugated with the amine residue to form Semaglutide API

Another side chain CAS RN 1169630-40-3 to be conjugated with the amine residue to form Semaglutide API

We offer two purity levels depending on your demand.

- 90% for the development of oral dosage form

- 98% for the development of injections

Due to the nature of peptide, we recommend the storage temperature at -15deg C to 20 deg C to avoid potential degradation.